Extracellular vesicles (EVs) have been implicated as important and sometimes sufficient mediators of the effects of stem cells. Best-practice models must be developed for the rapid development of exosomes, microvesicles, and other EVs as therapeutic entities.
Mesenchymal stem cells (MSCs) hold great potential as source for cell-based therapy for neurodegenerative diseases. In this review, we summarize recent progress using human MSC transplantation into rodent models of neurodegeneration. We examine the molecular mechanisms mediating disease amelioration through this approach and emphasize the potential of ex vivo manipulation for these cells before transplantation.
Researchers studying the effects of iPSC-MSCs treatment in an in vivo mouse model discover a novel immunomodulatory mechanism involving caspase proteins